VIROPIL is a triple fixed-dose combination antiretroviral therapy designed for the effective management of HIV-1. It works by targeting different stages of the HIV replication cycle to ensure long-term viral suppression.
How it works:
Dolutegravir inhibits HIV integrase, blocking viral integration
Lamivudine and Tenofovir inhibit reverse transcriptase, reducing viral replication
Recommended for:
Adults and adolescents over 12 years of age weighing ≥40 kg
Treatment-naïve individuals
Maintenance therapy for those already virologically suppressed
Treatment of HIV-1 infection in adults and adolescents
Initial ART or switching regimen with sustained viral suppression
Take one tablet once daily by mouth, with or without food. Adherence to daily dosing is essential for viral suppression. Therapy must be prescribed and monitored by a healthcare professional.
Hypersensitivity to any component
Severe renal impairment
Co-administration with rifampicin, St. John's wort, or drugs affecting metabolism
Insomnia
Headache
Nausea, diarrhoea
Elevated creatinine and liver enzymes
Reduced bone mineral density
Hypersensitivity reactions
